DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7xsp3l/primary) has announced the addition of the "Primary Hypogonadism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016" report to their offering.
Primary Hypogonadism - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.
A key objective of the Primary Hypogonadism Report is to understand the market and pipeline status of the drugs around the Primary Hypogonadism to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The Report provides the historical and forecasted sales of the drugs till 2018.
The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Primary Hypogonadism. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.
Key Topics Covered:
1. Indication Overview
2. Market Drugs Landscape
3. Global API Manufacturers Assessment
4. Phase III Drugs Landscape
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Primary Hypogonadism
7. Phase III Drugs for Primary Hypogonadism
8. Discontinued Drugs for Primary Hypogonadism
For more information visit http://www.researchandmarkets.com/research/7xsp3l/primary